lidocaine has been researched along with Respiratory Distress Syndrome in 19 studies
Lidocaine: A local anesthetic and cardiac depressant used as an antiarrhythmia agent. Its actions are more intense and its effects more prolonged than those of PROCAINE but its duration of action is shorter than that of BUPIVACAINE or PRILOCAINE.
lidocaine : The monocarboxylic acid amide resulting from the formal condensation of N,N-diethylglycine with 2,6-dimethylaniline.
Respiratory Distress Syndrome: A syndrome characterized by progressive life-threatening RESPIRATORY INSUFFICIENCY in the absence of known LUNG DISEASES, usually following a systemic insult such as surgery or major TRAUMA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A patient twice developed the adult respiratory distress syndrome following an adverse reaction to administration of lidocaine." | 7.66 | Adult respiratory distress syndrome following administration of lidocaine. ( Howard, JJ; Mohsenifar, Z; Simons, SM, 1982) |
| "The main objective of this study is to evaluate the effect of intravenous lidocaine on gas exchange and inflammation in acute respiratory distress syndrome due or not to Covid-19 pneumonia." | 5.41 | Impact of intravenous lidocaine on clinical outcomes of patients with ARDS during COVID-19 pandemia (LidoCovid): A structured summary of a study protocol for a randomised controlled trial. ( Aberkane, O; Becker, G; Chamaraux-Tran, TN; Glady, L; Harlay, ML; Hecketsweiler, S; Julians, M; Lefebvre, F; Muller, C; Muller, M; Pottecher, J; Romoli, A; Schneider, F; Tawk, M, 2021) |
| " Instead of using deep sedation and neuromuscular blockade, the authors hypothesized that perineural administration of lidocaine around the phrenic nerve would reduce tidal volume (VT) and peak transpulmonary pressure in spontaneously breathing patients with acute respiratory distress syndrome." | 4.12 | Phrenic Nerve Block and Respiratory Effort in Pigs and Critically Ill Patients with Acute Lung Injury. ( Adkson Sales Lima, C; Amato, MBP; Brochard, L; Costa, ELV; Goligher, EC; Ho, YL; Morais, CCA; Nakamura, MAM; Pereira, SM; Ranzani, OT; Sinedino, BE; Sklar, MC; Taniguchi, LU; Tucci, MR; Vieira, JE, 2022) |
| " Lidocaine, which prevents neutrophil adhesion to endothelial cells, inhibited granulocyte colony-stimulating factor-related exacerbation of acute lung injury (bronchoalveolar lavage fluid cells and pulmonary edema) and pulmonary fibrosis (lung static compliance and morphologic changes)." | 3.72 | Effect of granulocyte colony-stimulating factor on bleomycin-induced acute lung injury and pulmonary fibrosis. ( Azoulay, E; Brochard, L; Delclaux, C; Harf, A; Herigault, S; Levame, M; Schlemmer, B, 2003) |
| "A patient twice developed the adult respiratory distress syndrome following an adverse reaction to administration of lidocaine." | 3.66 | Adult respiratory distress syndrome following administration of lidocaine. ( Howard, JJ; Mohsenifar, Z; Simons, SM, 1982) |
| "Lidocaine has been reported to attenuate the inflammatory response in addition to its anesthetic activity, but the mechanisms are poorly understood." | 1.35 | Lidocaine attenuates lipopolysaccharide-induced acute lung injury through inhibiting NF-kappaB activation. ( Feng, G; Liu, GJ; Liu, S; Wang, GL, 2008) |
| "Lidocaine treatment attenuated these changes." | 1.31 | Lidocaine attenuates acute lung injury induced by a combination of phospholipase A2 and trypsin. ( Kiyonari, Y; Maekawa, N; Mikawa, K; Nishina, K; Obara, H, 2000) |
| "Lidocaine pretreatment attenuated these changes." | 1.29 | Effect of lidocaine pretreatment on endotoxin-induced lung injury in rabbits. ( Maekawa, N; Mikawa, K; Nishina, K; Obara, H; Takao, Y; Yaku, H, 1994) |
| "Lidocaine has been shown to inhibit neutrophil function." | 1.29 | Lidocaine attenuates hyperoxic lung injury in rabbits. ( Maekawa, N; Mikawa, K; Nishina, K; Obara, H; Takao, Y, 1996) |
| "Monoethylglycinexylidide (MEGX) is a hepatic metabolite of lidocaine, used clinically to determine graft function following hepatic transplantation." | 1.28 | Monoethylglycinexylidide production parallels changes in hepatic blood flow and oxygen delivery in lung injury managed with positive end-expiratory pressure. ( Branson, RD; Davis, K; Johnson, DJ; Purcell, PN; Schroeder, TJ, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (21.05) | 18.7374 |
| 1990's | 3 (15.79) | 18.2507 |
| 2000's | 7 (36.84) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 5 (26.32) | 2.80 |
| Authors | Studies |
|---|---|
| Hasan, D | 1 |
| Shono, A | 1 |
| van Kalken, CK | 1 |
| van der Spek, PJ | 1 |
| Krenning, EP | 1 |
| Kotani, T | 1 |
| Pereira, SM | 1 |
| Sinedino, BE | 1 |
| Costa, ELV | 1 |
| Morais, CCA | 1 |
| Sklar, MC | 1 |
| Adkson Sales Lima, C | 1 |
| Nakamura, MAM | 1 |
| Ranzani, OT | 1 |
| Goligher, EC | 1 |
| Tucci, MR | 1 |
| Ho, YL | 1 |
| Taniguchi, LU | 1 |
| Vieira, JE | 1 |
| Brochard, L | 2 |
| Amato, MBP | 1 |
| Ali, ZA | 1 |
| El-Mallakh, RS | 1 |
| Finnerty, DT | 1 |
| Buggy, DJ | 1 |
| Muller, M | 1 |
| Lefebvre, F | 1 |
| Harlay, ML | 1 |
| Glady, L | 1 |
| Becker, G | 1 |
| Muller, C | 1 |
| Aberkane, O | 1 |
| Tawk, M | 1 |
| Julians, M | 1 |
| Romoli, A | 1 |
| Hecketsweiler, S | 1 |
| Schneider, F | 1 |
| Pottecher, J | 1 |
| Chamaraux-Tran, TN | 1 |
| Azoulay, E | 1 |
| Herigault, S | 1 |
| Levame, M | 1 |
| Schlemmer, B | 1 |
| Harf, A | 1 |
| Delclaux, C | 1 |
| Huang, TK | 1 |
| Uyehara, CF | 1 |
| Balaraman, V | 1 |
| Miyasato, CY | 1 |
| Person, D | 1 |
| Egan, E | 1 |
| Easa, D | 1 |
| Govindarajan, R | 1 |
| Chaudhry, R | 1 |
| Babalola, O | 1 |
| Nguyen, N | 1 |
| Michael, R | 1 |
| Sultan, S | 1 |
| Sevimli, ZU | 1 |
| Dogan, N | 1 |
| Kizilkaya, M | 1 |
| Gundogdu, C | 1 |
| Feng, G | 1 |
| Liu, S | 1 |
| Wang, GL | 1 |
| Liu, GJ | 1 |
| Promisloff, RA | 1 |
| DuPont, DC | 1 |
| Woelke, BJ | 1 |
| Tucker, RA | 1 |
| Howard, JJ | 1 |
| Mohsenifar, Z | 1 |
| Simons, SM | 1 |
| Sutter, M | 1 |
| Pfenninger, J | 1 |
| Mikawa, K | 3 |
| Maekawa, N | 3 |
| Nishina, K | 3 |
| Takao, Y | 2 |
| Yaku, H | 1 |
| Obara, H | 3 |
| Kiyonari, Y | 1 |
| DePietro, MR | 1 |
| Eichacker, PQ | 1 |
| Purcell, PN | 1 |
| Branson, RD | 1 |
| Schroeder, TJ | 1 |
| Davis, K | 1 |
| Johnson, DJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Impact of Intravenous Lidocaine on Clinical Outcomes of Patients With ARDS During COVID-19 Pandemia[NCT04609865] | Phase 3 | 100 participants (Anticipated) | Interventional | 2020-11-04 | Recruiting | ||
| The Study of Perioperative Intravenous Infusion of Lidocaine on Postoperative Analgesia in Patients Undergoing Single-port Thoracoscopic[NCT04043624] | Phase 4 | 80 participants (Anticipated) | Interventional | 2019-08-01 | Recruiting | ||
| A Single Center, Randomized, Double-Blind Controlled Study of Topical Endoluminal Pancreatic Duct Lidocaine for Prevention of Post-ERCP Pancreatitis[NCT00953199] | 506 participants (Actual) | Interventional | 2010-03-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The primary outcome of interest will be development of acute pancreatitis defined as new or worsening abdominal pain post-ERCP associated with an increase in serum amylase at least 3 times the upper limit of normal. (NCT00953199)
Timeframe: 24-48 hours post-procedure
| Intervention | participants (Number) |
|---|---|
| Lidocaine | 26 |
| Normal Saline | 20 |
serum amylase levels are measure by a blood draw (NCT00953199)
Timeframe: measurement is taken 2 hrs after ERCP
| Intervention | units/liter (Mean) |
|---|---|
| Lidocaine | 130 |
| Normal Saline | 128 |
2 reviews available for lidocaine and Respiratory Distress Syndrome
| Article | Year |
|---|---|
A novel definition and treatment of hyperinflammation in COVID-19 based on purinergic signalling.
Topics: Adenosine Triphosphate; Anti-Inflammatory Agents; COVID-19; Critical Care; Cytokine Release Syndrome | 2022 |
Lidocaine for acute lung injury: questions still to answer.
Topics: Animals; Critical Illness; Disease Models, Animal; Drug Evaluation, Preclinical; Humans; Inflammatio | 2000 |
1 trial available for lidocaine and Respiratory Distress Syndrome
| Article | Year |
|---|---|
Impact of intravenous lidocaine on clinical outcomes of patients with ARDS during COVID-19 pandemia (LidoCovid): A structured summary of a study protocol for a randomised controlled trial.
Topics: Administration, Intravenous; Clinical Trials, Phase III as Topic; COVID-19; COVID-19 Drug Treatment; | 2021 |
16 other studies available for lidocaine and Respiratory Distress Syndrome
| Article | Year |
|---|---|
Phrenic Nerve Block and Respiratory Effort in Pigs and Critically Ill Patients with Acute Lung Injury.
Topics: Acute Lung Injury; Animals; Critical Illness; Disease Models, Animal; Female; Humans; Lidocaine; Phr | 2022 |
Nebulized Lidocaine in COVID-19, An Hypothesis.
Topics: Administration, Inhalation; Anesthetics, Local; Anti-Inflammatory Agents; COVID-19; COVID-19 Drug Tr | 2020 |
A novel role for lidocaine in COVID-19 patients?
Topics: Anesthetics, Local; Coronavirus Infections; COVID-19; Cytokines; Extracellular Traps; Humans; Lidoca | 2020 |
Effect of granulocyte colony-stimulating factor on bleomycin-induced acute lung injury and pulmonary fibrosis.
Topics: Animals; Antibiotics, Antineoplastic; Bleomycin; Cell Adhesion; Disease Models, Animal; Drug Evaluat | 2003 |
Surfactant lavage with lidocaine improves pulmonary function in piglets after HCl-induced acute lung injury.
Topics: Adjuvants, Immunologic; Animals; Bronchoalveolar Lavage; Disease Models, Animal; Drug Therapy, Combi | 2004 |
Airway management in acute respiratory distress secondary to tracheal stenosis following one time intubation.
Topics: Adolescent; Analgesics; Anesthesia, Inhalation; Anesthetics, Local; Asthma; Emergency Treatment; Fib | 2004 |
Experimental acute lung injury. Effects of methylprednisolone and lidocaine on histopathology and neutrophils.
Topics: Acute Disease; Animals; Anti-Inflammatory Agents; Chemotaxis, Leukocyte; Hydrochloric Acid; Lidocain | 2004 |
Lidocaine attenuates lipopolysaccharide-induced acute lung injury through inhibiting NF-kappaB activation.
Topics: Animals; Anti-Inflammatory Agents; Blotting, Western; Cytokines; Disease Models, Animal; Enzyme-Link | 2008 |
Death from ARDS and cardiovascular collapse following lidocaine administration.
Topics: Adult; Anaphylaxis; Female; Humans; Lidocaine; Respiratory Distress Syndrome | 1983 |
ARDS after local lidocaine administration.
Topics: Adult; Female; Humans; Intubation, Intratracheal; Lidocaine; Respiratory Distress Syndrome | 1983 |
Adult respiratory distress syndrome following administration of lidocaine.
Topics: Adenocarcinoma; Female; Humans; Intubation, Intratracheal; Lidocaine; Lung Neoplasms; Middle Aged; R | 1982 |
[Adult respiratory distress syndrome (ARDS) after poisoning by local anesthetics].
Topics: Arrhythmias, Cardiac; Child, Preschool; Dibucaine; Female; Humans; Intracranial Pressure; Lidocaine; | 1982 |
Effect of lidocaine pretreatment on endotoxin-induced lung injury in rabbits.
Topics: Animals; Bronchoalveolar Lavage Fluid; Capillary Permeability; Endotoxins; Hemodynamics; Infusions, | 1994 |
Lidocaine attenuates hyperoxic lung injury in rabbits.
Topics: Albumins; Anesthetics, Local; Animals; Bronchoalveolar Lavage Fluid; Capillary Permeability; Complem | 1996 |
Lidocaine attenuates acute lung injury induced by a combination of phospholipase A2 and trypsin.
Topics: Animals; Blood Gas Analysis; Disease Models, Animal; Disease Progression; Drug Evaluation, Preclinic | 2000 |
Monoethylglycinexylidide production parallels changes in hepatic blood flow and oxygen delivery in lung injury managed with positive end-expiratory pressure.
Topics: Animals; Blood Flow Velocity; Critical Illness; Disease Models, Animal; Dogs; Evaluation Studies as | 1992 |